Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are closely related disorders, linked pathologically and genetically by the TAR DNA-binding protein-43 (TDP-43). Pathogenic variants in TARDBP encoding for TDP-43 have been described less frequently in FTD than in ALS, and clinicopathological studies are scarce.1 We previously observed a high frequency of the I383V variant in TARDBP in a Dutch cohort of FTD patients.2 Here, we provide further evidence for the pathogenicity of this variant and present its clinicopathological characteristics.
We ascertained all FTD (n=13) and ALS patients (n=4) with the I383V variant (NM_007375.3: c.1147A>G, p.Ile383Val) in TARDBP from three university medical centres in the Netherlands (Amsterdam, Rotterdam and Utrecht), as identified by whole-exome or whole-genome sequencing in either clinical or research setting. Concurrent pathogenic variants in 20 other genes associated with ALS, FTD or other forms of dementia were excluded in all patients.
Brain imaging (CT or MRI) was available for all FTD patients. Quantitative assessment of volume loss across lobar brain regions was performed in those patients with T1-weighted MRI images of sufficient quality (n=5), and compared with a gender-matched/age-matched reference population.
Family histories were classified into adjusted Goldman categories, which were described previously.2 Additionally, we performed extensive genealogical research to investigate possible relatedness between the index patients.
Brain autopsy and routine immunohistochemistry was performed for two FTD patients by the Netherlands Brain Bank. One patient (4M) was reported previously as M008015-001.1 Detailed information on the genetic, neuroimaging, genealogical and pathological analyses can be found in the1.
Results and discussion
The variable clinical phenotype and reduced penetrance of the I383V variant
All 13 FTD patients with the I383V variant in TARDBP presented with a combination of behavioural changes and semantic deficits. The diagnoses of semantic variant of primary progressive aphasia (svPPA) are intriguing since this is usually considered a sporadic disorder. One patient (4M) showed additional motor symptoms, but not fulfilling ALS criteria. Of the 4 ALS patients with the I383V variant, 3 had a relatively slow progression with the longest disease duration of 9 years. None of the ALS patients exhibited cognitive or behavioural symptoms. Clinical details are presented in online supplemental tables 1,2.
Six FTD patients and one ALS patient were found to be related (family 1). Additionally, two FTD patients and two ALS patients (families 2 and 3) could be linked to family 1 through a distant common ancestor (figure 1). The variable phenotype of the I383V variant is exemplified by family 1, in which different family members were affected by svPPA, behavioural variant of FTD, unspecified dementia, ALS or progressive spinal muscular atrophy, with a wide range in age at onset (44–69 years) and disease duration (7–23 years). Interestingly, several obligate carriers were unaffected, suggesting incomplete penetrance even at an advanced age (>80 years). Larger prospective studies are required to estimate age-related penetrance.
Four remaining families (online supplemental figure 1) did not show a clear pattern of autosomal dominant inheritance (Goldman 2–5). In one of these families, an affected relative with the I383V variant was clinically diagnosed with Alzheimer’s disease (AD), but AD biomarker changes were not evaluated in cerebrospinal fluid. A possible explanation is that the dementia in this patient is coincidental and unrelated to the I383V variant. Alternatively, increased susceptibility for AD caused by the I383V variant may be considered. Another interesting hypothesis is that TARDBP variants might be associated with limbic-predominant age-related TDP-43 encephalopathy, a common age-related disorder with TDP-43 proteinopathy that clinically mimics AD.3
Several other relatives, including obligate carriers, were affected by psychiatric disorders such as psychosis and schizophrenia with onset around 40–50 years. Unfortunately, detailed clinical information or DNA were not available for these subjects. Whether psychiatric disorders are part of the I383V–TARDBP spectrum remains to be investigated in future studies. Altogether, our observations illustrate large phenotypic variability of the I383V variant and incomplete penetrance.
Isolated bitemporal atrophy in FTD patients with the I383V variant
The most discriminating feature of the I383V variant is the predominant and severe atrophy of the temporal lobes in all FTD patients, with relative sparing of the other lobes (figure 1 and online supplemental figure 2). This is in line with previous observations in I383V FTD patients and the frequent occurrence of semantic deficits and prosopagnosia in our patients (online supplemental table 1). Other pathogenic TARDBP variants (eg, K263E) are associated with a more variable pattern of lobar atrophy.1 However, predominant temporal involvement has also been reported for other TARDBP variants located nearby the I383V variant (eg, A382T),4 suggesting a specific effect of missense variants in this part of the C-terminal domain of TDP-43. Further functional studies are needed to elucidate these possible genotype–phenotype correlations.
Heterogeneous pathological features in TARDBP patients
A remarkable observation is the scarcity of TDP-43 reactivity in the cortical areas of two FTD patients (patient 1F and the previously reported patient 4M1), despite the underlying pathogenic TARDBP variant. Only several TDP-43 cytoplasmic inclusions of various morphologies were found in the frontal cortex, dentate gyrus and caudate nucleus (figure 1). A possible explanation for the scarce temporal pathology might be the severe neurodegeneration, especially considering the long disease duration of patient 1F (23 years). Interestingly, we also detected tau positive inclusions in the hippocampus and tufted astrocytes in the putamen and caudate nucleus (figure 1). A single other neuropathological study of a I383V carrier reported similar low amounts of TDP-43 inclusions, and the presence of α-synuclein deposits and tauopathy, including tufted astrocytes in the amygdala.5 It appears that the neuropathological changes in FTD caused by variants in TARDBP are not readily classifiable. Whether the detected co-pathologies occurred by chance needs to be determined in additional cases with TDP-43 variants.
Classification of the I383V variant as likely pathogenic
Our findings indicate a pathogenic effect of the I383V variant, which was previously debated due to the more conservative amino acid substitution and the benign in silico predictions by SIFT and PolyPhen. The current families, especially family 1, clearly show segregation of the variant with the disease, although penetrance appears incomplete. In addition to the patients described here, the I383V variant has been previously reported in 16 FTD and 8 ALS patients (online supplemental table 3), with frequencies ranging from 0% to 0.9% in ALS cohorts and from 0% to 2.5% in clinical FTD cohorts, while the variant is consistently absent in large groups of healthy controls from different populations. These data additionally support its pathogenicity. This conclusion has clinical implications for genetic counselling of patients and unaffected family members, to whom presymptomatic testing and counselling can now be offered.
Our study provides sufficient evidence for the pathogenicity of the I383V variant and contributes to the characterisation of TARDBP-related FTD. We demonstrate the large phenotypic variability and incomplete penetrance of the I383V variant. Marked isolated bitemporal volume loss in all FTD patients should prompt clinicians to genetically test for causal variants in TARDBP.
Patient consent for publication
Approval of the study was provided by the Medical Ethics Review Board of the Erasmus Medical Center of Rotterdam (MEC-2019-170) and the Amsterdam Medical Center (MEC-2016-061). Ethical approval for the Netherlands Brain Bank (NBB) procedures and forms was given by the Medical Ethics Committee of the VU Medical Center, Amsterdam. Informed consent for the use of clinical and neuropathological data was obtained from all participants or their legal representatives. Brain autopsy was performed by the NBB at the designated premises of the VU Medical Center according to the code of conduct for Brain Banking and Declaration of Helsinki.
We are indebted to all the patients who made this study possible. We also thank R. van 't Klooster from Quantib for assistance with the quantified volumetric data.
MOM and SW.N contributed equally.
Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.
Contributors MOM and SWRN designed and conceptualised the study, analysed and interpreted all data, and drafted and submitted the manuscript. YALP, SJL, LDK, MRJM, WR, MAE and JHV played a major role in the acquisition of data and revised the manuscript. JGJR, RM and RMLS analysed and interpreted the genetic data, and revised the manuscript. MV analysed and interpreted the neuroimaging data, and revised the manuscript. AJMR analysed and interpreted the pathological data. EAMH conducted genealogical research. JCVS, PCH, HS and EGPD designed and conceptualised the study, revised the manuscript and are responsible for the overall content as guarantors.
Funding This project has received funding from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 772376 – ESCORIAL).
Competing interests Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases: Project ID No. 739510. JHV reports to have sponsored research agreements with Biogen.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.